Stryker Co. (NYSE:SYK) Shares Bought by Addison Advisors LLC

Addison Advisors LLC raised its position in Stryker Co. (NYSE:SYK) by 1.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,043 shares of the medical technology company’s stock after purchasing an additional 75 shares during the quarter. Addison Advisors LLC’s holdings in Stryker were worth $1,456,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Dunhill Financial LLC lifted its holdings in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Stryker in the 4th quarter worth approximately $30,000. BankPlus Trust Department acquired a new position in shares of Stryker in the 4th quarter worth approximately $33,000. Darwin Wealth Management LLC acquired a new position in shares of Stryker in the 3rd quarter worth approximately $36,000. Finally, Activest Wealth Management acquired a new position in shares of Stryker in the 4th quarter worth approximately $36,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Price Performance

Shares of NYSE:SYK opened at $388.11 on Tuesday. The company’s fifty day moving average price is $378.38 and its 200 day moving average price is $369.78. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market capitalization of $148.09 billion, a P/E ratio of 50.01, a P/E/G ratio of 2.93 and a beta of 0.96.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the company posted $3.46 EPS. As a group, sell-side analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.87%. Stryker’s dividend payout ratio is currently 43.30%.

Analyst Ratings Changes

Several brokerages recently weighed in on SYK. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, January 30th. The Goldman Sachs Group upped their target price on shares of Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research note on Thursday, January 30th. Royal Bank of Canada upped their target price on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 target price on shares of Stryker in a research note on Wednesday, January 29th. Finally, Stifel Nicolaus upped their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $422.15.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.